Literature DB >> 7808443

Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells.

R W Klecker1, A G Katki, J M Collins.   

Abstract

Two cell lines, U-937 and MOLT-4, were used to investigate the toxicity, DNA incorporation, and effect on mitochondria of 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) and its putative metabolite 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-uracil (FAU). After 72-hr incubation, the IC50 values for FIAU were 6.4 microM for U-937 cells and 26 microM for MOLT-4 cells. IC50 values for FAU were 10-fold higher in both cell lines. Incubation for 24 hr with 10 microM [2-14C]FIAU led to 2.1% and 0.93% replacement of thymidine in DNA of U-937 and MOLT-4 cells, respectively. The predominant radioactive species measurable in DNA was FIAU. A similar incubation with [2-14C]FAU resulted in 4-fold lower DNA incorporation of a single radioactive species that coeluted with 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). There was no evidence of a selective repair process after DNA incorporation of FIAU or FAU (FMAU). Increased intracellular concentrations of FIAU triphosphate and incorporation into DNA were associated with an increase in cellular toxicity. Continuous exposure to a clinically achievable concentration of FIAU, 0.44 microM, produced a constant DNA incorporation of 0.80% and 0.11% for U-937 and MOLT-4 cells, respectively. FIAU was not readily metabolized to FAU or iodouracil by human liver in vitro. Compared with 2',3'-dideoxycytidine as a positive control, after 12 days of continuous exposure of U-937 and MOLT-4 cells to FIAU there was no evidence of increased lactate production. These data negate several possible mechanisms (DNA chain termination, DNA polymerase inhibition, one form of selective mitochondrial poisoning, and FAU-mediated toxicity) and provide clues for possible mechanisms (FIAU triphosphate concentration and DNA incorporation). Further work is needed to develop a complete explanation for the delayed hepatic toxicity observed in the investigational clinical trials of FIAU.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808443

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides.

Authors:  Anne B Neef; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Mitochondrial injury. Lessons from the fialuridine trial.

Authors:  P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Measurement of the incorporation and repair of exogenous 5-hydroxymethyl-2'-deoxyuridine in human cells in culture using gas chromatography-negative chemical ionization-mass spectrometry.

Authors:  Daniel K Rogstad; Agus Darwanto; Jason L Herring; Katherine Noyes Rogstad; Artur Burdzy; Scott R Hadley; Jonathan W Neidigh; Lawrence C Sowers
Journal:  Chem Res Toxicol       Date:  2007-10-04       Impact factor: 3.739

4.  Selection, design, and characterization of a new potentially therapeutic ribozyme.

Authors:  Shawn P Zinnen; Kristal Domenico; Mike Wilson; Brent A Dickinson; Amber Beaudry; Victor Mokler; Andrew T Daniher; Alex Burgin; Leonid Beigelman
Journal:  RNA       Date:  2002-02       Impact factor: 4.942

5.  Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts.

Authors:  W Lewis; E S Levine; B Griniuviene; K O Tankersley; J M Colacino; J P Sommadossi; K A Watanabe; F W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

6.  Differential effects of the incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences.

Authors:  K A Staschke; K K Richardson; T E Mabry; A J Baxter; J C Scheuring; D M Huffman; W C Smith; F C Richardson; J M Colacino
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

Review 7.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 8.  A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial disease.

Authors:  Christopher M Bailey; Karen S Anderson
Journal:  Biochim Biophys Acta       Date:  2010-01-18

Review 9.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

10.  In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression.

Authors:  Mian M Alauddin; Antranic Shahinian; Ryan Park; Michel Tohme; John D Fissekis; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.